Does the media refer more to ONC or TGTX?

In the previous week, BeOne Medicines had 5 more articles in the media than TG Therapeutics. MarketBeat recorded 11 mentions for BeOne Medicines and 6 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.59 beat BeOne Medicines' score of -0.18 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or TGTX?

In the previous week, TG Therapeutics had 3 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for TG Therapeutics and 3 mentions for BioNTech. BioNTech's average media sentiment score of 0.85 beat TG Therapeutics' score of 0.59 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, TGTX or ROIV?

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $700.35M 11.79 $447.18M $2.86 18.86 Roivant Sciences $8.26M 2,804.80 -$299.77M -$0.60 N/A

Does the media favor TGTX or ROIV?

In the previous week, Roivant Sciences had 3 more articles in the media than TG Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for TG Therapeutics. Roivant Sciences' average media sentiment score of 1.49 beat TG Therapeutics' score of 0.59 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, INSM or TGTX?

TG Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 36.51 -$1.28B -$5.75 N/A TG Therapeutics $700.35M 11.79 $447.18M $2.86 18.86

Is INSM or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Insmed's net margin of -144.44%. TG Therapeutics' return on equity of 88.73% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% TG Therapeutics 65.95% 88.73% 43.44%

Does the media prefer INSM or TGTX?

In the previous week, Insmed had 7 more articles in the media than TG Therapeutics. MarketBeat recorded 13 mentions for Insmed and 6 mentions for TG Therapeutics. Insmed's average media sentiment score of 1.32 beat TG Therapeutics' score of 0.59 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TGTX or MRNA more profitable?

TG Therapeutics has a net margin of 65.95% compared to Moderna's net margin of -143.55%. TG Therapeutics' return on equity of 88.73% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 65.95% 88.73% 43.44% Moderna -143.55% -26.64% -19.32%

Does the media favor TGTX or MRNA?

In the previous week, Moderna had 37 more articles in the media than TG Therapeutics. MarketBeat recorded 43 mentions for Moderna and 6 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.59 beat Moderna's score of 0.40 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 17 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 12 Negative mention(s) 0 Very Negative mention(s) Neutral

TG Therapeutics (TGTX) Competitors

$53.94 -0.46 (-0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$53.95 +0.01 (+0.02%)

As of 06:36 PM Eastern

Compare

TGTX vs. ONC, BNTX, ROIV, INSM, and MRNA

Should you buy TG Therapeutics stock or one of its competitors? MarketBeat compares TG Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TG Therapeutics include BeOne Medicines (ONC), BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does TG Therapeutics compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

In the previous week, BeOne Medicines had 5 more articles in the media than TG Therapeutics. MarketBeat recorded 11 mentions for BeOne Medicines and 6 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.59 beat BeOne Medicines' score of -0.18 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BeOne Medicines currently has a consensus target price of $390.00, suggesting a potential upside of 41.24%. TG Therapeutics has a consensus target price of $58.60, suggesting a potential upside of 8.64%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe BeOne Medicines is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

TG Therapeutics has a net margin of 65.95% compared to BeOne Medicines' net margin of 8.94%. TG Therapeutics' return on equity of 88.73% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has lower revenue, but higher earnings than BeOne Medicines. TG Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.67	$286.93M	$4.47	61.77
TG Therapeutics	$700.35M	11.79	$447.18M	$2.86	18.86

Summary

TG Therapeutics beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

TG Therapeutics has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.06	-$1.29B	-$5.88	N/A
TG Therapeutics	$700.35M	11.79	$447.18M	$2.86	18.86

BioNTech has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market.

BioNTech currently has a consensus target price of $129.56, suggesting a potential upside of 42.97%. TG Therapeutics has a consensus target price of $58.60, suggesting a potential upside of 8.64%. Given BioNTech's higher probable upside, research analysts clearly believe BioNTech is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

TG Therapeutics has a net margin of 65.95% compared to BioNTech's net margin of -44.39%. TG Therapeutics' return on equity of 88.73% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
TG Therapeutics	65.95%	88.73%	43.44%

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, TG Therapeutics had 3 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for TG Therapeutics and 3 mentions for BioNTech. BioNTech's average media sentiment score of 0.85 beat TG Therapeutics' score of 0.59 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats BioNTech on 11 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Roivant Sciences?

TG Therapeutics (NASDAQ:TGTX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$700.35M	11.79	$447.18M	$2.86	18.86
Roivant Sciences	$8.26M	2,804.80	-$299.77M	-$0.60	N/A

TG Therapeutics has a net margin of 65.95% compared to Roivant Sciences' net margin of -3,629.19%. TG Therapeutics' return on equity of 88.73% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TG Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

In the previous week, Roivant Sciences had 3 more articles in the media than TG Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for TG Therapeutics. Roivant Sciences' average media sentiment score of 1.49 beat TG Therapeutics' score of 0.59 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics presently has a consensus target price of $58.60, suggesting a potential upside of 8.64%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential upside of 4.29%. Given TG Therapeutics' higher possible upside, equities analysts clearly believe TG Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

TG Therapeutics beats Roivant Sciences on 10 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

In the previous week, Insmed had 7 more articles in the media than TG Therapeutics. MarketBeat recorded 13 mentions for Insmed and 6 mentions for TG Therapeutics. Insmed's average media sentiment score of 1.32 beat TG Therapeutics' score of 0.59 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.6% of TG Therapeutics shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.51	-$1.28B	-$5.75	N/A
TG Therapeutics	$700.35M	11.79	$447.18M	$2.86	18.86

TG Therapeutics has a net margin of 65.95% compared to Insmed's net margin of -144.44%. TG Therapeutics' return on equity of 88.73% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
TG Therapeutics	65.95%	88.73%	43.44%

Insmed currently has a consensus target price of $211.86, suggesting a potential upside of 107.40%. TG Therapeutics has a consensus target price of $58.60, suggesting a potential upside of 8.64%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts plainly believe Insmed is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

TG Therapeutics beats Insmed on 10 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Moderna?

TG Therapeutics (NASDAQ:TGTX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TG Therapeutics presently has a consensus target price of $58.60, indicating a potential upside of 8.64%. Moderna has a consensus target price of $36.60, indicating a potential downside of 40.00%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TG Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

TG Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$700.35M	11.79	$447.18M	$2.86	18.86
Moderna	$1.94B	12.45	-$2.82B	-$8.15	N/A

TG Therapeutics has a net margin of 65.95% compared to Moderna's net margin of -143.55%. TG Therapeutics' return on equity of 88.73% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 37 more articles in the media than TG Therapeutics. MarketBeat recorded 43 mentions for Moderna and 6 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.59 beat Moderna's score of 0.40 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	17 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	12 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Summary

TG Therapeutics beats Moderna on 12 of the 17 factors compared between the two stocks.

Get TG Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TGTX vs. The Competition

Export

Metric	TG Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.26B	$3.45B	$6.47B	$12.11B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	18.86	20.09	24.71	24.00
Price / Sales	11.79	297.62	519.55	102.13
Price / Cash	18.99	56.54	27.92	37.84
Price / Book	13.22	8.28	10.82	6.53
Net Income	$447.18M	$23.85M	$3.56B	$336.99M
7 Day Performance	6.73%	5.21%	1.68%	-0.22%
1 Month Performance	38.77%	2.18%	0.44%	0.77%
1 Year Performance	47.54%	60.99%	32.84%	31.57%

TG Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TGTX TG Therapeutics	2.9923 of 5 stars	$53.94 -0.8%	$58.60 +8.6%	+51.0%	$8.26B	$700.35M	18.86	290	Analyst Forecast
ONC BeOne Medicines	4.1468 of 5 stars	$268.20 +1.4%	$390.00 +45.4%	+10.0%	$29.02B	$5.34B	60.00	12,000	Analyst Downgrade
BNTX BioNTech	4.5365 of 5 stars	$90.80 +0.3%	$129.56 +42.7%	-15.3%	$22.90B	$3.25B	N/A	7,807
ROIV Roivant Sciences	1.8735 of 5 stars	$30.03 0.0%	$33.59 +11.9%	+172.9%	$21.61B	$8.26M	N/A	860	Positive News
INSM Insmed	3.4857 of 5 stars	$97.46 -0.4%	$212.50 +118.0%	-4.0%	$21.21B	$606.42M	N/A	1,664	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TGTX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TG Therapeutics (TGTX) Competitors

TGTX vs. ONC, BNTX, ROIV, INSM, and MRNA

How does TG Therapeutics compare to BeOne Medicines?

Summary

How does TG Therapeutics compare to BioNTech?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Summary

How does TG Therapeutics compare to Insmed?

Summary

How does TG Therapeutics compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TG Therapeutics (TGTX) Competitors

TGTX vs. ONC, BNTX, ROIV, INSM, and MRNA

How does TG Therapeutics compare to BeOne Medicines?

Does the media refer more to ONC or TGTX?

Which has more risk & volatility, ONC or TGTX?

Do institutionals & insiders hold more shares of ONC or TGTX?

Do analysts prefer ONC or TGTX?

Is ONC or TGTX more profitable?

Which has higher earnings and valuation, ONC or TGTX?

Summary

How does TG Therapeutics compare to BioNTech?

Which has stronger valuation & earnings, BNTX or TGTX?

Which has more volatility and risk, BNTX or TGTX?

Do analysts prefer BNTX or TGTX?

Is BNTX or TGTX more profitable?

Do insiders and institutionals hold more shares of BNTX or TGTX?

Does the media prefer BNTX or TGTX?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Which has preferable valuation & earnings, TGTX or ROIV?

Is TGTX or ROIV more profitable?

Do institutionals and insiders hold more shares of TGTX or ROIV?

Which has more volatility and risk, TGTX or ROIV?

Does the media favor TGTX or ROIV?

Do analysts recommend TGTX or ROIV?

Summary

How does TG Therapeutics compare to Insmed?

Does the media prefer INSM or TGTX?

Do institutionals & insiders have more ownership in INSM or TGTX?

Which has more volatility and risk, INSM or TGTX?

Which has better valuation and earnings, INSM or TGTX?

Is INSM or TGTX more profitable?

Do analysts rate INSM or TGTX?

Summary

How does TG Therapeutics compare to Moderna?

Do insiders and institutionals believe in TGTX or MRNA?

Do analysts prefer TGTX or MRNA?

Which has preferable valuation & earnings, TGTX or MRNA?

Is TGTX or MRNA more profitable?

Does the media favor TGTX or MRNA?

Which has more volatility and risk, TGTX or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools